About Tubulin beta-4A chain
Tubulin beta-4A chain (TUBB4A) is a protein
from Homo sapiens identified by UniProt accession
P04350, 444 residues long.
MolForge cross-references it against 0 known binders and
831 disease associations.
Target properties
| Protein name | Tubulin beta-4A chain |
| UniProt accession | P04350 |
| Gene | TUBB4A |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (831)
Diseases linked to this target (Open Targets).
- Primary dystonia, DYT4 type · score 0.79
- hypomyelinating leukodystrophy 6 · score 0.72
- Hypomyelination with atrophy of basal ganglia and cerebellum · score 0.72
- torsion dystonia 4 · score 0.71
- neoplasm · score 0.61
- head and neck squamous cell carcinoma · score 0.61
- breast cancer · score 0.61
- non-small cell lung carcinoma · score 0.61
- breast carcinoma · score 0.60
- ovarian cancer · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04350-F1 | alphafold | PREDICTED | 92.17 | — |
Amino-acid sequence (444 residues)
MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS DLQLERINVY YNEATGGNYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF VFGQSGAGNN WAKGHYTEGA ELVDAVLDVV RKEAESCDCL QGFQLTHSLG GGTGSGMGTL LISKIREEFP DRIMNTFSVV PSPKVSDTVV EPYNATLSVH QLVENTDETY CIDNEALYDI CFRTLKLTTP TYGDLNHLVS ATMSGVTTCL RFPGQLNADL RKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT QQMFDAKNMM AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LSVQSKNSSY FVEWIPNNVK TAVCDIPPRG LKMAATFIGN STAIQELFKR ISEQFTAMFR RKAFLHWYTG EGMDEMEFTE AESNMNDLVS EYQQYQDATA EEGEFEEEAE EEVA
Explore Tubulin beta-4A chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets